Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes

Author： Rosenstock J. Aguilar-Salinas C. Klein E. Nepal S. List J. Chen R.

E-ISSN： 0300-7995|25|10|2401-2411

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.25, Iss.10, 2009-10, pp. : 2401-2411

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Saxagliptin for the treatment of type 2 diabetes mellitus: Focus on recent studies

By Schwartz Sherwyn L.

Annals of Medicine, Vol. 44, Iss. 2, 2012-03 ,pp. : 157-169

Informa Healthcare

Access to resources Recommend Favorite

Saxagliptin: a New DPP-4 inhibitor for the treatment of type 2 diabetes mellitus

By Tahrani Abd Piya Milan Barnett Anthony

Advances in Therapy, Vol. 26, Iss. 7, 2009-07 ,pp. : 736-736

Springer Publishing Company

Access to resources Recommend Favorite

Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug‐naïve patients with type 2 diabetes: a randomized, double‐blind, 6‐month study

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 16, Iss. 7, 2014-07 ,pp. : 613-621

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 7, 2015-07 ,pp. : 630-638

John Wiley & Sons Inc

Access to resources Recommend Favorite

Seven‐year safety and efficacy with velaglucerase alfa for treatment‐naïve adult patients with type 1 Gaucher disease

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : 577-583

John Wiley & Sons Inc

Access to resources Recommend Favorite